GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study To Investigate The Safety, Tolerability And Blood Levels Of GSK598809
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2017-08-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT00437840
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults
- Conditions
- Nausea and Vomiting, Chemotherapy-Induced
- Interventions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 37
- Registration Number
- NCT00437229
- Locations
- 🇺🇸
GSK Investigational Site, Buffalo, New York, United States
Brain Metastases In ErbB2-Positive Breast Cancer
- Conditions
- Neoplasms, Breast
- Interventions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2015-10-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 22
- Registration Number
- NCT00437073
- Locations
- 🇸🇪
GSK Investigational Site, Uppsala, Sweden
Pharmacoeconomic Consequences Of Analgesia in the Intensive Care Unit (ICU)
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 39
- Registration Number
- NCT00436345
- Locations
- 🇮🇹
GSK Investigational Site, Palermo, Sicilia, Italy
Odiparcil QT Definitive Study
- Conditions
- Fibrillation, AtrialAtrial Fibrillation
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 54
- Registration Number
- NCT00437242
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
A Study To Assess GW677954 Used In Combination With Insulin In Subjects Who Have Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes MellitusDiabetes Mellitus, Type 2
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT00437164
- Locations
- 🇺🇸
GSK Investigational Site, Beverly Hills, California, United States
To Study And Compare Bioavailability And Safety Of Four Different Formulations Of The Study Drug
- Conditions
- Healthy Subjects
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2008-10-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 32
- Registration Number
- NCT00436228
- Locations
- 🇺🇸
GSK Investigational Site, Tacoma, Washington, United States
Implementing Hospital-based Active Surveillance Procedures for Vaccine Safety Monitoring at IMSS Hospitals in Mexico
- Conditions
- IntussusceptionLRTI-related Post Neonatal Deaths
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2011-01-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 134
- Registration Number
- NCT00436358
- Locations
- 🇲🇽
GSK Investigational Site, Mexico DF, Mexico
Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen
- Conditions
- Malaria
- Interventions
- Biological: GSK 257049Biological: Tritanrix™ HepB/HibBiological: Rouvax™Biological: Polio Sabin™Biological: Stamaril™
- First Posted Date
- 2007-02-16
- Last Posted Date
- 2018-08-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 511
- Registration Number
- NCT00436007
- Locations
- 🇹🇿
GSK Investigational Site, Dar-es-Salaam, Tanzania
A Study of Patient Management in HIV-1 Infected Patients Found to Have the Genetic Marker HLA-B*5701
- Conditions
- HIV Infection
- First Posted Date
- 2007-02-16
- Last Posted Date
- 2008-10-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 35
- Registration Number
- NCT00435838
- Locations
- 🇨🇭
GSK Investigational Site, La Chaux-de-Fonds, Switzerland